Patient characteristics and the Livin expression rates
| Characteristic . | No. of patients . | Livin expression, no. (%) . | P . |
|---|---|---|---|
| Sex | |||
| Female | 84 | 28 (33.3) | |
| Male | 138 | 29 (21.0) | .042 |
| Age | |||
| 1 y to less than 10 y | 161 | 49 (30.4) | |
| At least 10 y or younger than 1 y | 61 | 8 (13.1) | .008 |
| Leukocyte count | |||
| Less than 50 × 109/L | 166 | 49 (29.5) | |
| At least 50 × 109/L | 56 | 8 (14.3) | .024 |
| Risk group | |||
| Standard-risk patients | 129 | 42 (32.6) | |
| High-risk patients | 93 | 15 (16.1) | .006 |
| Immunophenotype | |||
| Precursor B cell | 171 | 45 (26.3) | |
| Others | 49 | 12 (24.5) | .797 |
| Number of chromosomes | |||
| 50 or more | 26 | 1 (3.8) | |
| 45-49 | 168 | 48 (28.6) | |
| 44 or fewer | 9 | 3 (33.3) | .023 |
| Structural abnormalities of chromosome | |||
| t(12;21) | 35 | 29 (82.9) | |
| Absent or others | 155 | 27 (17.4) | |
| t(9;22) or 11q23 rearrangement | 32 | 1 (3.1) | < .001 |
| CSF involvement | |||
| Absent | 193 | 49 (25.4) | |
| Present | 12 | 1 (8.3) | .182 |
| Mediastinal involvement | |||
| Absent | 215 | 57 (26.5) | |
| Present | 7 | 0 (0) | .114 |
| Day 7 BM response to treatment | |||
| Leukemic blasts less than 25% | 143 | 50 (35.0) | |
| Leukemic blasts at least 25% | 69 | 6 (8.7) | < .001 |
| Relapse | |||
| No | 185 | 56 (30.3) | |
| Yes | 37 | 1 (2.7) | < .001 |
| Characteristic . | No. of patients . | Livin expression, no. (%) . | P . |
|---|---|---|---|
| Sex | |||
| Female | 84 | 28 (33.3) | |
| Male | 138 | 29 (21.0) | .042 |
| Age | |||
| 1 y to less than 10 y | 161 | 49 (30.4) | |
| At least 10 y or younger than 1 y | 61 | 8 (13.1) | .008 |
| Leukocyte count | |||
| Less than 50 × 109/L | 166 | 49 (29.5) | |
| At least 50 × 109/L | 56 | 8 (14.3) | .024 |
| Risk group | |||
| Standard-risk patients | 129 | 42 (32.6) | |
| High-risk patients | 93 | 15 (16.1) | .006 |
| Immunophenotype | |||
| Precursor B cell | 171 | 45 (26.3) | |
| Others | 49 | 12 (24.5) | .797 |
| Number of chromosomes | |||
| 50 or more | 26 | 1 (3.8) | |
| 45-49 | 168 | 48 (28.6) | |
| 44 or fewer | 9 | 3 (33.3) | .023 |
| Structural abnormalities of chromosome | |||
| t(12;21) | 35 | 29 (82.9) | |
| Absent or others | 155 | 27 (17.4) | |
| t(9;22) or 11q23 rearrangement | 32 | 1 (3.1) | < .001 |
| CSF involvement | |||
| Absent | 193 | 49 (25.4) | |
| Present | 12 | 1 (8.3) | .182 |
| Mediastinal involvement | |||
| Absent | 215 | 57 (26.5) | |
| Present | 7 | 0 (0) | .114 |
| Day 7 BM response to treatment | |||
| Leukemic blasts less than 25% | 143 | 50 (35.0) | |
| Leukemic blasts at least 25% | 69 | 6 (8.7) | < .001 |
| Relapse | |||
| No | 185 | 56 (30.3) | |
| Yes | 37 | 1 (2.7) | < .001 |
Differences in Livin expression rates were analyzed using the Pearson chi-square test. Statistical significance was accepted when P values were less than .05.